Companies look for profit in orphan drugs

Thompson, Cheryl A.
November 2010
American Journal of Health-System Pharmacy;11/15/2010, Vol. 67 Issue 22, p1892
Academic Journal
The article focuses on several pharmaceutical companies and their initiatives related to the development and commercialization of orphan drugs. It says that GlaxoSmithKline established a unit that specializes in drugs for rare diseases. It states that Pfizer Inc. formed the Orphan and Genetic Diseases Research Unit in addition to its specialty care business unit focusing on orphan drugs. It also mentions that Amicus Therapeutics Inc. is engaged in developing drugs for uncommon diseases.


Related Articles

  • Spare a thought for “orphan” drugs. Brooks, Michael // New Statesman;2/27/2015, p18 

    The article looks at orphan drugs, or drugs developed to treat rare diseases. The author lauds policies in Europe and the U.S. to spur the development of orphan drugs by subsidizing research on them but says their high cost can make it difficult to provide them to patients once developed. Topics...

  • PhRMA beats Obama administration again in 340B battle. Schencker, Lisa // Modern Healthcare;10/19/2015 THE BEST PLACES TO WORK IN HEALTHCARE, Vol. 45 Issue  

    The article reports on the decision by a federal judge to reject the policy by the administration of U.S. President Barack Obama to provide rural and cancer hospitals discounts on orphan drugs. The Pharmaceutical Research and Manufacturers of America has filed a lawsuit twice over the Department...

  • Time to revisit the orphan drug law. Garattini, Silvio // European Journal of Clinical Pharmacology;Feb2012, Vol. 68 Issue 2, p113 

    The author reflects on an orphan drug law which was approved by the European Parliament to encourage pharmaceutical companies to develop drugs for approximately 7,000 rare diseases awaiting a therapy. The author suggests that while drugs are costly to develop, there is no doubt that...

  • European policies on orphan diseases and drugs stimulate drug development, but could be improved.  // Drugs & Therapy Perspectives;May2011, Vol. 27 Issue 5, p24 

    The EU implemented policies specifically designed to stimulate the development of drugs for the treatment of orphan diseases. However, the current system used to make decisions on orphan designation has several limitations. Policies relating to the treatment of orphan diseases require a...

  • Hope for Orphan Drugs in Act.  // Pharmaceutical Representative;Jul2011, Vol. 41 Issue 7, p8 

    The article discusses the Creating Hope Act of 2011 intended for rare and pediatric orphan diseases in the U.S.

  • Policymaking for Orphan Drugs and Its Challenges. Rhee, Taeho Greg // AMA Journal of Ethics;Aug2015, Vol. 17 Issue 8, p776 

    The article discusses policymaking for drugs and biologics for rare diseases or conditions, also known as orphan drugs, Orphan Drug Act (ODA) successes such as increased diversity of orphan drugs, and issues not addressed by ODA like high medication costs affecting accessibility.

  • Will crowdfunding and general solicitation spur orphan drug development for biotechs? Loucks, David // Formulary;Oct2013, Vol. 48 Issue 10, p343 

    The article presents information on the efforts of the U.S. Food and Drug Administration (FDA) to enhance orphan drug development. It states that FDA has offered many incentives to biotech firms to motivate them to increase the production of orphan drugs. It also discusses the benefits of equity...

  • THE ORPHAN DRUG ACT AND THE MYTH OF THE EXCLUSIVITY INCENTIVE. Rogoyski, Robert // Columbia Science & Technology Law Review;2008, Vol. 9, p1 

    For more than 20 years, the marketing exclusivity provision of the Orphan Drug Act has been hailed as a key component of the incentive for the United States' pharmaceutical industry to develop drugs for rare disorders; this is the Official Story of the ODA. In this paper, I argue that the...

  • WEEK IN WASHINGTON.  // BioWorld Insight;8/29/2011, Vol. 19 Issue 35, p6 

    The article offers news briefs related to pharmaceutical industry in the U.S. including the conflict of interest rules released by the National Institute of Health (NIH) for lower reporting threshold, the strategic plan released by the Food and Drugs Administration (FDA) for regulatory science,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics